{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-276845","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-06-22T13:17:24+00:00","discovered_at":"2026-06-22T13:18:00.317471+00:00","generated_at":"2026-06-22T13:18:11.859913+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure","bullets":["Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.","Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.","Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.","Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.","CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-276845","json":"https://secwatch.observer/filing/0001193125-26-276845.json","markdown":"https://secwatch.observer/filing/0001193125-26-276845.md","text":"https://secwatch.observer/filing/0001193125-26-276845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/0001193125-26-276845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/d27128d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:18:11.859913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}